FDA Cannot Regulate Stem Cell Treatments, DC Circ. Hears
Regenerative Sciences' counsel Andrew S. Ittleman accused the agency of trying to gain “limitless authority” over the medical practice by claiming its Regenexx procedure had violated the Federal Food, Drug and Cosmetic Act by shipping its components across state lines.
The Regenexx procedure — which uses a...
To view the full article, register now.